Oncology Learning Center CME Podcasts
By Oncology Learning Center
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Podcast Description
These are the CME-Accredited podcasts from Oncology Learning Center symposia. Please visit http://www.olccme.com/enduring/ to review the latest CME-Accredited materials. Moreover, on our Web site, you will also be able to download or view the presentations, download the audio, or complete an evaluation form to receive CME credit. The Oncology Learning Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
| Name | Description | Released | Price | ||
|---|---|---|---|---|---|
|
1 |
Panel Discussion, Q and A, and Consensus on the Status of the Data Presented in Session 4 | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
2 |
Session 4: Case Study | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
3 |
Point-Counterpoint: All patients receiving an anti-EGFR therapy for thoracic malignancies should be screened for the EGFR mutat | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
4 |
Anti-EGFR treatment strategies in the maintenance setting for patients with NSCLC | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
5 |
Panel Discussion and Q and A: Audience asks faculty about the value and clinical application of any commercially available diag | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
6 |
EGFR and KRAS testing: new roles for pathology and molecular diagnostics | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
7 |
Developing treatment strategies for managing inherent and acquired resistance to anti-EGFR therapy for NSCLC in both wild type | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
8 |
Personalizing therapies for thoracic malignancies with anti-EGFR treatment strategies | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
9 |
Panel Discussion, Q and A, and Consensus on the Status of the Data Presented in Session 3 | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
10 |
Session 3 Case Study | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
11 |
Point-Counterpoint: Chemotherapy plus an anti-VEGF monoclonal antibody is a standard of care for patients eligible for this reg | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
12 |
Can we personalize the combination of anti-angiogenesis systemic therapy plus radiation and also with anti-EGFR systemic therap | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
13 |
Dual targeting strategies utilizing anti-angiogenic and anti-EGFR agents in combination therapy as multi-targeted agents | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
14 |
Using molecular biomarkers for devising personalized therapy strategies with anti-angiogenic agents for thoracic malignancies | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
15 |
Personalizing therapies for thoracic malignancies with anti-VEGF monoclonal antibodies against the receptor and against the lig | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
16 |
Personalizing therapies for thoracic malignancies with anti-angiogenesis small molecules | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
17 |
Panel Discussion, Q and A, and Consensus on the Status of the Data Presented in Session 2 | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
18 |
Session 2 Case Study | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
19 |
Point-Counterpoint: We have reached the maximum benefits with chemotherapy for treating thoracic malignancies | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
20 |
Novel agents and new treatment strategies for SCLC | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
21 |
New clinical applications of chemotherapy plus radiation for thoracic malignancies. Can this combined-modality approach be pers | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
22 |
The clinical applications of maintenance chemotherapy for NSCLC | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
23 |
Studies of molecular markers to personalize head and neck cancer therapy | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
24 |
Personalizing chemotherapy for lung cancer | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
25 |
Current best clinical practices using systemic therapy for treating thoracic malignancies. Have personalized regimens of chemot | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
26 |
Investigational drugs in late stage development for lung cancer | CME-Accredited Internet-Based activity from Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer | 1/10/10 | Free | View In iTunes |
|
27 |
Case Study #4: A patient with unresectable Stage IV metastatic melanoma tested for SPARC | CME-Accredited Internet-Based activity from Using Biomarkers to Maximize Novel Taxane Therapies in Multiple Tumor Types: Case-Based Learning | 7/8/09 | Free | View In iTunes |
|
28 |
Case Study #3: A patient with locally advanced, early-stage breast cancer, tested for ER/PR, HER2, SPARC, the 21 genomic assay | CME-Accredited Internet-Based activity from Using Biomarkers to Maximize Novel Taxane Therapies in Multiple Tumor Types: Case-Based Learning | 7/8/09 | Free | View In iTunes |
|
29 |
Case Study #2: A previously untreated patient with metastatic non-small cell lung cancer of adenocarcinoma histology, tested fo | CME-Accredited Internet-Based activity from Using Biomarkers to Maximize Novel Taxane Therapies in Multiple Tumor Types: Case-Based Learning | 7/8/09 | Free | View In iTunes |
|
30 |
Case Study #1: A previously untreated patient with advanced pancreatic cancer tested for CA 19-9 and SPARC | CME-Accredited Internet-Based activity from Using Biomarkers to Maximize Novel Taxane Therapies in Multiple Tumor Types: Case-Based Learning | 7/8/09 | Free | View In iTunes |
|
31 |
Panel Discussion, QA, and Consensus on the Status of the Data Presented in this Session | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
32 |
Session 7 Case Study | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
33 |
Point-Counterpoint: Drugs treating bone metastases should be offered to patients as an option for adjuvant therapy of breast ca | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
34 |
Newer clinical strategies for treating bone metastases | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
35 |
Drugs treating bone metastases: are they supportive care agents, therapeutics, or both? | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
36 |
Panel Discussion, QA, and Consensus on the Status of the Data Presented in this Session | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
37 |
Session 6 Case Studies | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
38 |
Point-Counterpoint: All triple-negative patients should receive platinum-based adjuvant therapy | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
39 |
Therapeutic individualization with specific chemotherapeutic agents | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
40 |
Personalizing breast cancer therapies using anti-angiogenic strategies | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
41 |
Pathology and molecular classification of Triple-Negative Carcinoma | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
42 |
Panel Discussion, QA, and Consensus on the Status of the Data Presented in this Session | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
43 |
Session 5 Case Study | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
44 |
Point-Counterpoint: Systemic therapy for the elderly should be identical to that for younger patients | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
45 |
Personalized approaches to treating patients with ER+ breast cancer using single nucleotide polymorphisms (SNPs) | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
46 |
Are there personalized strategies for overcoming resistance to endocrine therapy? | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
47 |
What are the molecular predictors of response to adjuvant endocrine therapy? | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
48 |
Panel Discussion, QA, and Consensus on the Status of the Data Presented in this Session | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
49 |
Point-Counterpoint: A taxane plus an alkylating agent should replace anthracycline-based therapies for adjuvant therapy of HER2 | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
50 |
Point-Counterpoint: Adjuvant anti-HER2 therapy should be considered for HER2-negative patients? | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
51 |
The relationship between HER2 expression and response to taxane-based therapies | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
52 |
Predictors of response and personalized approaches for selecting patients with HER2+ breast cancer for adjuvant and neo-adjuvan | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
53 |
Personalized approaches to selecting targeted therapies and chemotherapies for metastatic HER2+ breast cancer patients | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
54 |
Panel Discussion, QA, and Consensus on the Status of the Data Presented in this Session | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
55 |
Point-Counterpoint: T[a taxane]+ C[a platinum]+ H[an anti-HER2] should replace anthracycline-based therapies for adjuvant thera | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
56 |
Personalizing surgical therapy for breast cancer | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
57 |
Personalizing radiation therapy for breast cancer | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
58 |
Individualizing local-regional control with neo-adjuvant chemotherapy | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
59 |
Panel Discussion, QA, and Consensus on the Status of the Data Presented in this Session | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
60 |
Session 2 Case Study | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
61 |
Point-Counterpoint: Use the 70-gene microarray assay versus the 21-gene panel assay for testing ER+, node-negative breast cance | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
62 |
Response to Neoadjuvant Chemotherapy: what we can predict to do and what we cannot | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
63 |
In which patients with breast cancer are gene expression arrays beneficial as prognostic markers today? | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
64 |
Panel Discussion, QA and Consensus on the Status of the Data Presented in this Session | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
65 |
Session 1 Case Study | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
66 |
Point-CounterPoint #1: All patients at high risk for developing breast cancer should receive SERMS prophylactically. | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
67 |
Drug prevention strategies using SERMS and other agents for patients at high risk of developing breast cancer. | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
68 |
The clinical application of genetic testing for breast cancer prevention. | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
|
69 |
Predicting who will develop breast cancer. | CME-Accredited Enduring Material activity from Second Annual Symposium on Personalized Therapies for Breast Cancer | 3/9/09 | Free | View In iTunes |
| Total: 69 Episodes |
Listeners also subscribed to
- Dana-Farber Master Class CME Podcast Series
- Dana-Farber Cancer Institute
- View In iTunes
- Oncology Unplugged
- The CBCE
- View In iTunes
- Oncology Times Broadcast News
- Oncolgy Times & Audio Medica
- View In iTunes
- Oncology Conference News
- OncoEd, Inc.
- View In iTunes
